Deemed “fantastic” by a leukemia expert, phase I data presented by Agios Pharmaceuticals Inc. snagged the spotlight Sunday at the American Association for Cancer Research (AACR) meeting in San Diego, with isocitrate dehydrogenase-2 (IDH2)-targeting candidate AG-221 producing a complete remissions (CRs) in three of seven evaluable patients.